![Phillipe Lutz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Phillipe Lutz
Plus aucun poste en cours
Profil
Phillipe Lutz served as the Chief Financial Officer at Synosia Therapeutics AG and Telormedix SA. He holds an MBA from the University of St. Gallen.
Anciens postes connus de Phillipe Lutz
Sociétés | Poste | Fin |
---|---|---|
Synosia Therapeutics AG
![]() Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Directeur Financier/CFO | - |
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | Directeur Financier/CFO | - |
Formation de Phillipe Lutz
University of St. Gallen | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
Telormedix SA
![]() Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | Health Technology |
Synosia Therapeutics AG
![]() Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |